• Molecular NameAmlexanox
  • Synonymamlexanox; Amlexanox [USAN:INN:JAN]; Amlexanoxo [Spanish]; Amlexanoxum [Latin]
  • Weight298.298
  • Drugbank_IDDB01025
  • ACS_NO68302-57-8
  • Show 2D model
  • LogP (experiment)3.26
  • LogP (predicted, AB/LogP v2.0)2.68
  • pkaN/A
  • LogD (pH=7, predicted)-0.4
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.26
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors3
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds2
  • TPSA102.51
  • StatusFDA approved
  • AdministrationTopical
  • PharmacologyA medication with antiallergic and anti-inflammatory effects used in the treatment of aphthous ulcers (canker sores).
  • Absorption_valueN/A
  • Absorption (description)No significant absorption directly through the active ulcer. Most of the systemic absorption is via the gastrointestinal tract.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMetabolized to hydroxylated and conjugated metabolites.
  • Half life3.5 h
  • ExcretionRenal (17%)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A